Published in Cardiorenal Med on November 24, 2012
Overnutrition, mTOR signaling, and cardiovascular diseases. Am J Physiol Regul Integr Comp Physiol (2014) 1.01
Fructose and uric acid: is there a role in endothelial function? Curr Hypertens Rep (2014) 1.01
Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. J Diabetes Investig (2014) 0.88
Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives. Endocrinol Metab Clin North Am (2013) 0.86
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes (2014) 0.86
Therapy of obese patients with cardiovascular disease. Curr Opin Pharmacol (2013) 0.79
Estrogen and mitochondria function in cardiorenal metabolic syndrome. Prog Mol Biol Transl Sci (2014) 0.79
Effect of the FTO rs9930506 Polymorphism on the Main Comorbidities of the Cardiorenal Metabolic Syndrome in an Elderly Spanish Cohort. Cardiorenal Med (2014) 0.75
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser (2000) 70.59
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res (1998) 50.73
Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA (2012) 33.54
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med (2009) 13.91
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation (1983) 12.63
Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) (2009) 12.45
Body weight and mortality among women. N Engl J Med (1995) 11.04
Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief (2012) 10.88
Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care (2008) 9.34
A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med (2003) 9.23
A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med (2003) 8.00
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (2009) 7.24
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med (2002) 6.92
Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med (2010) 6.63
Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med (2012) 6.19
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care (2011) 5.50
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care (2004) 5.34
A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med (2004) 4.81
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (2010) 4.23
Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis (1990) 4.01
Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med (2007) 3.97
The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg (2006) 3.97
Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med (2010) 3.73
Obesity and risk for chronic renal failure. J Am Soc Nephrol (2006) 3.67
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest (1998) 3.18
Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg (2004) 2.62
Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA (2005) 2.58
Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA (1978) 2.54
Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int (2004) 2.44
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) (2010) 2.25
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) (2011) 2.09
WHO recognition of the global obesity epidemic. Int J Obes (Lond) (2008) 1.99
A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab (2011) 1.98
Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. Arch Intern Med (1991) 1.94
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr (2011) 1.94
Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke (2010) 1.87
Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial. Obesity (Silver Spring) (2011) 1.84
Bariatric surgery: a systematic review and network meta-analysis of randomized trials. Obes Rev (2011) 1.68
Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) (2012) 1.66
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab (2009) 1.52
Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord (2003) 1.38
Nutritional deficiencies after bariatric surgery. Nat Rev Endocrinol (2012) 1.37
The Role of Overweight and Obesity in the Cardiorenal Syndrome. Cardiorenal Med (2011) 1.35
Restricted-carbohydrate diets in patients with type 2 diabetes: a meta-analysis. J Am Diet Assoc (2008) 1.28
Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis (2003) 1.26
Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function. J Am Coll Cardiol (2009) 1.17
Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am J Med (2011) 1.16
Multi-hit nature of chronic renal disease. Curr Opin Nephrol Hypertens (2000) 1.16
Metabolic risk factors and renal disease. Kidney Int (2007) 1.14
Acute kidney injury after gastric bypass surgery. Clin J Am Soc Nephrol (2007) 1.07
Pharmacologic therapies for obesity. Gastroenterol Clin North Am (2010) 1.07
Albuminuria in people at least 40 years old: effect of obesity, hypertension, and hyperlipidemia. Clin Chem (1992) 1.07
Physical activity in the prevention and treatment of hypertension in the obese. Med Sci Sports Exerc (1999) 1.06
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med (2000) 0.99
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J Clin Pharm Ther (2011) 0.96
Food and Drug Administration's Obesity Drug Guidance Document: a short history. Circulation (2012) 0.94
Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron (1995) 0.93
Indices of obesity and cardiometabolic risk. Hypertension (2011) 0.92
Effects of two weight-loss diets on health-related quality of life. Qual Life Res (2009) 0.92
Medical therapy for the patient with obesity. Circulation (2012) 0.90
Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials. Obes Rev (2009) 0.85
Low-carbohydrate diets: an update on current research. Curr Diab Rep (2009) 0.83
Impact of body mass index and waist circumference on the cardiovascular risk and all-cause death in a general population: data from the PAMELA study. Nutr Metab Cardiovasc Dis (2012) 0.83
Metformin: an update. Ann Intern Med (2002) 5.62
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Role of mitochondrial dysfunction in insulin resistance. Circ Res (2008) 3.45
Hypertension, angiotensin II, and oxidative stress. N Engl J Med (2002) 1.92
Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) (2010) 1.90
Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol (2004) 1.73
CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.71
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol (2007) 1.71
Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol (2011) 1.69
Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine (2004) 1.64
Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem (2006) 1.62
Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc (2006) 1.60
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol (2005) 1.59
Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care (2002) 1.59
AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension (2003) 1.57
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis (2009) 1.52
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich) (2005) 1.51
ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich) (2008) 1.50
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol (2008) 1.48
Epidemiology of diabetes. J Clin Pharmacol (2004) 1.47
Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab (2007) 1.46
Redox control of renal function and hypertension. Antioxid Redox Signal (2008) 1.45
Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes (2013) 1.45
Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab (Lond) (2008) 1.44
Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol (2007) 1.39
Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab (2007) 1.36
Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab (2004) 1.33
NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension (2007) 1.32
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension (2010) 1.32
Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun (2003) 1.31
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology (2007) 1.31
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol (2006) 1.30
The metabolic syndrome: role of skeletal muscle metabolism. Ann Med (2006) 1.28
Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism (2013) 1.27
Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab (2011) 1.25
The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med (2011) 1.23
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension (2008) 1.23
Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep (2004) 1.22
Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab (2008) 1.22
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci (2012) 1.21
Hypertension and obesity. Recent Prog Horm Res (2004) 1.20
Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord (2013) 1.19
Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology (2013) 1.19
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol (2009) 1.18
Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology (2009) 1.18
The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol (2004) 1.16
Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol (2008) 1.16
Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.16
Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology (2013) 1.15
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab (2008) 1.15
The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol (2005) 1.14
The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am (2009) 1.13
Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol (2010) 1.13
Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.12
Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Am J Physiol Regul Integr Comp Physiol (2011) 1.12
Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol (2008) 1.12
Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis (2010) 1.12
IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction. Am J Physiol Regul Integr Comp Physiol (2008) 1.11
Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology (2007) 1.11
Hypertension in obesity. Med Clin North Am (2011) 1.10
Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol (2003) 1.09
Heart disease in diabetic patients. Curr Diab Rep (2003) 1.09
Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin (2012) 1.07
The role of tissue Renin-Angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol (Lausanne) (2013) 1.06
Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol (2008) 1.06
Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J Cardiometab Syndr (2008) 1.06
Isletopathy in Type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress. Antioxid Redox Signal (2007) 1.05
Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 1.04
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int (2010) 1.04
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol (2014) 1.04
Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol (2011) 1.03
Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology (2010) 1.03
Oxidative stress in the cardiorenal metabolic syndrome. Curr Hypertens Rep (2012) 1.02
Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol (2011) 1.02
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) (2005) 1.02
Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol (2009) 1.02
Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv Chronic Kidney Dis (2006) 1.01
Stroke in patients with diabetes and hypertension. J Clin Hypertens (Greenwich) (2005) 1.01
Overweight female rats selectively breed for low aerobic capacity exhibit increased myocardial fibrosis and diastolic dysfunction. Am J Physiol Heart Circ Physiol (2012) 1.01
The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney. Cardiorenal Med (2011) 1.01
Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. Am J Nephrol (2007) 1.01
Fructose and uric acid: is there a role in endothelial function? Curr Hypertens Rep (2014) 1.01
Contribution of oxidative stress to pulmonary arterial hypertension. World J Cardiol (2010) 1.00
Low aerobic capacity and high-fat diet contribute to oxidative stress and IRS-1 degradation in the kidney. Am J Nephrol (2009) 1.00
Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism (2009) 1.00
Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. Am J Physiol Renal Physiol (2006) 0.99
Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension (2008) 0.99
Role of aldosterone and angiotensin II in insulin resistance: an update. Clin Endocrinol (Oxf) (2008) 0.99
Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Am J Nephrol (2007) 0.99
Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. Endocrinology (2012) 0.99
Mitochondria and Oxidative Stress in the Cardiorenal Metabolic Syndrome. Cardiorenal Med (2012) 0.98
Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep (2003) 0.98
Relation between Childhood Obesity and Adult Cardiovascular Risk. Int J Pediatr Endocrinol (2009) 0.98
Hypertension and insulin resistance. Hypertension (2009) 0.98
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol (2010) 0.97
Pericytopathy: oxidative stress and impaired cellular longevity in the pancreas and skeletal muscle in metabolic syndrome and type 2 diabetes. Oxid Med Cell Longev (2010) 0.97
New insights into insulin action and resistance in the vasculature. Ann N Y Acad Sci (2014) 0.97
Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats. Am J Physiol Endocrinol Metab (2013) 0.96